Cancers, Vol. 12, Pages 293: Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
Cancers, Vol. 12, Pages 293: Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
Cancers doi: 10.3390/cancers12020293
Authors:
Chuma
Uojima
Numata
Hidaka
Toyoda
Hiraoka
Tada
Hirose
Atsukawa
Itokawa
Arai
Kako
Nakazawa
Wada
Iwasaki
Miura
Hishiki
Nishigori
Morimoto
Hattori
Ogushi
Nozaki
Fukuda
Kagawa
Michitaka
Kumada
Maeda
Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast growth factor 19 (FGF19), FGF23, and angiopoietin-2 (Ang-2) were measured using enzyme-linked immunosorbent assays. Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 ...
Source: Cancers - Category: Cancer & Oncology Authors: Chuma Uojima Numata Hidaka Toyoda Hiraoka Tada Hirose Atsukawa Itokawa Arai Kako Nakazawa Wada Iwasaki Miura Hishiki Nishigori Morimoto Hattori Ogushi Nozaki Fukuda Kagawa Michitaka Kumada Maeda Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Children | Hepatocellular Carcinoma | Liver Cancer | Study